title: Taxanes in ovarian cancer treatment.
abstract: Paclitaxel and docetaxel are active in the treatment of patients with advanced ovarian cancer. The taxanes in various dose schedules achieve response rates of 10-50% with a median overall survival of 10-12 months in patients with platinum-refractory disease. Paclitaxel has activity in chemotherapy-naive patients when administered alone or in combination with platinum. The role of intraperitoneal paclitaxel remains to be defined.
authors.affiliation: Pramongkutklao College of Medicine, Bangkok, Thailand.
authors.forename: K
authors.initials: K
authors.lastname: Seetalarom
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015996:Survival Rate; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel